$Soligenix (SNGX.US)$ NEWS Positive Clinical Results from Hy...
NEWS
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
Soligenix announced positive results from its HyBryte™ compatibility study for treating cutaneous T-cell lymphoma (CTCL), published in JEADV Clinical Practice. The study, HPN-CTCL-02, enrolled 9 patients, revealing a 22% treatment response rate after 8 weeks of HyBryte™ therapy. The results align with the Phase 3 FLASH trial, showing an average improvement of 36.4% in cumulative mCAILS scores. Key metrics included low systemic hypericin levels and no adverse effects on cardiac rhythm, confirming HyBryte™'s safety. The study points to the potential real-world use of HyBryte™ and precedes a confirmatory Phase 3 FLASH2 study.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
751Followers
75Following
4811Visitors
Follow
MangoXXXX : How come it’s not jumping yet
Jaguar8OP MangoXXXX: Just wait later